17 May 2016
A pioneering treatment for patients with chronic bronchitis has been carried out for the first time in the UK as part of a trial led by experts at Royal Brompton Hospital and Chelsea and Westminster Hospital in London.
The 30-minute procedure, which uses liquid nitrogen to freeze diseased lung tissue from the upper layer of cells in the airways, was carried out by Trust consultant respiratory physician Dr Pallav Shah, as part of the RejuvenAir System clinical trial.
The clinical trial, which is taking place at Royal Brompton Hospital, in collaboration with Chelsea and Westminster Hospital NHS Foundation Trust, and at the University Medical Center Groningen in the Netherlands, aims to evaluate the safety and feasibility of the treatment.
The minimally-invasive treatment targets the goblet cells, which are found in the top layer of airway tissue (the epithelium) and produce excessive amounts of mucus in patients with chronic bronchitis. The procedure aims to destroy these cells using liquid nitrogen, while preserving the stem cells underneath. The stem cells allow new, healthy tissue to quickly form within a few days.
Chronic bronchitis is the most common form of chronic obstructive pulmonary disease (COPD), a condition that is thought to affect around three million people in the UK.
Dr Shah explains: “The main cause of chronic bronchitis is smoking, because the immune system triggers the goblet cells to produce too much mucus. The excess mucus blocks the airways, causing cough and breathlessness, and attracts bacteria which can lead to infections.
“While some medications available to patients can thin the mucus or open the airways, this new procedure is the only treatment that has the potential to stop excess mucus production and restore it to a normal level.”
Jayne Hewitt, 49, from London, became the first patient in the UK to have the novel procedure. She was diagnosed with COPD around four years ago after suffering from breathlessness, a tight chest, frequent chest infections and a persistent cough. Her condition progressively worsened until it got to the point where simple daily tasks, such as having a bath, carrying shopping, talking and eating, were a struggle.
She said: “It’s amazing to be the first UK patient to have this treatment and I feel so privileged to be given this opportunity. Days later my chest already didn’t feel as tight, I was coughing less than before and breathing a bit better, even though only one part of my right lung had been treated.
“It used to feel like I had an elephant sitting on my chest and now it doesn’t. It has given me such a boost and I feel more hopeful about my future now.”
The trial is funded by CSA Medical, the company that manufacturers the RejuvenAir System.
Find out more about this clinical trial